Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Patent
1998-01-23
2000-10-03
Slobodyansky, Elizabeth
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
530300, 530324, 530326, 435194, C07K 1900, C07K 1447, C07K 1100, C07K 1400, C12N 912
Patent
active
061275212
ABSTRACT:
The present invention relates to the discovery of novel proteins of mammalian origin which are immediate downstream targets for FKBP/rapamycin complexes.
REFERENCES:
patent: 3929992 (1975-12-01), Sehgal et al.
patent: 5283317 (1994-02-01), Saifer et al.
patent: 5322772 (1994-06-01), Soldin
patent: 5354845 (1994-10-01), Soldin
Kunz et al. (May 7, 1993) Cell 73, pp. 585-596.
Alarcon, C. et al., "Mammalian RAFT1 Kinase Domain Provides Rapamycin-sensitive TOR Function in Yeast", Genes Dev. 10(3).
Albers, M. et al., "FKBP-Rapamycin Inhibits a Cyclin-dependent Kinase activity and a Cyclin D1-Cdk Association in Early G1 of an Osteosarcoma Cell Line", J. Biol. Chem. 268: 22825-22829 (1993).
Barbet, N. et al., "TOR Controls Translation Initiation and Early G1 Progression in Yeast", Mol. Biol. Cell 7(1): 25-42 (1996).
Bierer, B. et al., Probing Immunosuppressant Action with a Nonnatural Immunophilin Ligand, Science 250: 556-559 (1990).
Bierer, B. et al., "Two Distinct Signal Transmission Pathways in T Lymphochtes are Inhibited by Complexes Formed between an Immunophilin and either FK506 or Rapamycin", Proc. Nat. Acad. Sci. USA 87: 231-9235 (1990).
Brown, . Et al., "A Mammalian Protein Targeted by G1-arresting Rapamycin-receptor Complex", Nature 369: 756-758 (1994).
Cafferkey, R. et al., "Dominant Missense Mutations in a Novel Yeast Protein Related to Mammalian Phosphatidylinositol 3-Kinase and VPS34 Abrogate Rapamycin Cytotoxicity", Mol. Cell. Biol.13:6012-6023 (1993).
Cafferkey, R. et al., "Yeast TOR (DRR) Proteins: Amino-acid Sequence Alignment and Identification of Structural Motifs", Gene 141: 133-136 (1994).
Cardenas, M. and Heitman, J. "FKBP12-rapamycin Target TOR2 is a Vacuolar Protein with an Associated Phosphatidylinositol-4 Kinase Activity", EMBO J.14(23): 5892-5907 (1995).
Chui, M. et al., "RAPT1, a Mammalian Homolog of Yeast Tor, Interacts with the FKBP12/rapamycin Complex", Proc. Nat. Acad. Sci. USA 91: 12574-12578 (1994).
Chung, J. et al., "Rapamycin-FKBP Specifically Blocks Growth-Dependent Activation of and Signaling by the 70 kd S6 Protein Kinases", Cell69: 1227-1236 (1992).
DiLella, A. and Craig, R., "Exon Organization of the Human FKBP-12 Gene: Correlation with Structural and Functional Protein Domains", Biochem. 30: 8512-8517 (1991).
Draetta, G., "Cell Cycle Control in Ekaryotes: Molecular Mechanisms of cdc2 Activation", Trends Biol. Sci. 15: 378-383 (1990).
Dumont, F. et al., "The Immunosuppressive Macrolides FK-506 and Rapamycin Act as Reciprocal Antagonists in Murine T Cells", J. Immunol. 144: 1418-1424 (1990).
Ferrara, A. et al., "Cloning and Sequence Analysis of a Rapamycin-binding Protein-encoding Gene (RBP1) from Candida albicans", Gene 113: 125-127 (1992).
Francavilla, A. et al., "Effects of Rapamycin on Cultured Hepatocyte Proliferation and Gene Expression", Hepatol. 15: 871-877 (1992).
Freeman, K. and Livi, G., "Missense Mutations at the FKBP12-rapamycin-binding Site of TOR1", Gene 172(1): 143-147 (1996).
Fruman, D. et al. "Immunophilins in Protein Folding and Immunosuppression", FASEB J. 8: 391-400 (1994).
Galat, A. "Peptidylproline cis-trans-isomerases: Immunophilins", Eur. J. Biochem. 216: 689-707 (1993).
Harding, M. et al., "A Receptor for the Immunosuppressant FK506 is a cis-trans Peptidyl-prolyl Isomerase", Nature 341: 758-760 (1989).
Heitman, J. et al., "Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast", Science 253: 905-909 (1991).
Helliwell, S. et al., "TOR1 and TOR2 are Structurally and Functionally Similar but not Identical Phosphatiylinositol Kinase Homologues in Yeast", Mol. Biol. Cell. 5: 105-118 (1994).
Huang, M. et al., Analysis of a 62 kb DNA Sequence of Chromosome X Reveals 36 Open Reading Frames and a Gene Cluster with a Counterpart on Chromosome XI, Yeast 12(9): 869-875 (1996).
Kato, R. and Ogawa, H., "An Essential Gene, ESR1, is Required for Mitotic Cell Growth, DNA Repair and Meiotic Recombination in Saccharomyces cerevisiae", Nucl.eic Acid Res. 22(15): 3104-3112 (1994).
Kunz, J. et al., "Target of Rapamycin in Yeast, TOR2, Is an Essential Phosphatidylinositol Kinase Homolog Required for G.sub.1 Progression", Cell 73: 585-596 (1993).
Lorenz, M. and Heitman, J., "TOR Mutations Confer Rapamycin Resistance by Preventing Interaction with FKBP12-Rapamycin", J. Biol. Chem. 270(46): 27531-27537 (1995).
Morice, W. et al., "Rapamycin-induced Inhibition of p34.sup.cdc2 Kinase Activation is Associated with G.sub.1 /S-phase Growth Arrest in T Lymphocytes", J. Biol. Chem. 268: 3734-3738 (1993).
Pardee, A., "G.sub.1 Events and Regulation of Cell Proliferation", Science 246: 603-608 (1989).
Price, D. et al., "Rapamycin-Induced Inhibition of the 70-Kilodalton S6 Protein Kinase", Science 257:973-977 (1992).
Sabatini, D. et al., "The Rapamycin and FKBP12 Target (RAFT) Displays Phosphatidylinositol 4-Kinase Activity", J. Biol. Chem. 270(36): 20875-20878 (1995).
Sabatini, D. et al., "RAFT1: A Mammalian Protein that Binds to FKBP12 in a Rapamcycin-dependent Fashion and is Homologous to Yeast TORs", Cell 78: 35-38 (1994).
Sabers, C. et al., "Isolation of a Protein Target of the FKBP12-rapamycin Complex in Mammalian Cells", J. Biol. Chem. 270: 815-822 (1995).
Schmidt, A. et al., "TOR2 is Required for Organization of the Actin Cytoskeleton in Yeast", Proc. Nat. Acad. Sci. USA 93(24): 13780-13785 (1996).
Schreiber, S., "Immunophilin-sensitive Protein Phosphatase Action in Cell Signaling Pathways", Cell 70: 365-368 (1992).
Schreiber, S. and Crabtree, G., "The Mechanism of Action of Cyclosporin A and FK506", Immunol. Today 13: 136-142 (1992).
Sehgal, S. et al., "Rapamycin (AY-22,989), A New Antifungal Antibiotic. II. Fermentation, Isolation and Characterization", J. Antibiotics 28: 727-732 (1975).
Sherr, C., "Mammalian G.sub.1 Cyclins", Cell 73: 1059-1065 (1993).
Siekierka, J. et al., A Cytosolic Binding Protein for the Immunosuppressant FK506 has Peptidylprolyl Isomerase Activity but is Distinct from Cyclophilin:, Nature 341: 755-757 (1989).
Sigal, N. and Dumont, F., "Cyclosporin A, FK-506, And Rapamycin: Pharmacologic Probes of Lymphocyte Signal Transduction", Ann. Rev. Immunol. 10: 519-560 (1992).
Sigal, N. et al., "Inhibition of Human T-cell Activation by FK 506, Rapamycin, and Cyclosporine A", Transplantation Proc. 23 (2 Supp. 2): 1-5 (1991).
Silver, L. et al., "TOR1 is a Novel, Variant Form of Mouse Chromosome 17 with a Deletion in a Partial T Haplotype", Nature 301(5899): 422-424 (1983).
Soltoff, S. et al., "Nerve Growth Factor Promotes the Activation of Phosphatidylinositol 3-Kinase and its Association with the trk Tryosine Kinase", J. Biol. Chem. 267: 17472-17477 (1992).
Stan, R. et al., "Interaction between FKBP12-rapamycin and TOR Involves a Conserved Serine Residue", J. Biol. Chem. 269(51): 32027-32030 (1994).
Van Duyne, G. et al., "Atomic Structure of FKBP-FK506, an Immunophilin-immunosuppressant Complex", Science 252: 839-843 (1991).
Van Duyne, G. et al., "Atomic Structures of the Human Immunophilin FKBP-12 Complexes with FK506 and Rapamycin", J. Mol. Biol. 229: 105-124 (1993).
Vezina, C. et al., "Rapamycin (AY-22,989), a New Antifungal Antibiotic. I. Taxonomy of the Producing Streptomycete and Isolation of the Active Principle", J. Antibiotics 28: 721-726 (1975).
Walsh, C. et al., "Cyclosporin A, the Cylophilin Class of Peptidylprolyl Isomerases, and Blockade of T Cell Signal Transduction", J. Biol. Chem. 267: 13115-13118 (1992).
Zheng, X. et al., "TOR Kinase Domains are Required for Two Distinct Functions, Only One of which is Inhibited by Rapamycin", Cell 82(1): 121-130 (1995).
Berlin, V. "Identification of Novel Immunosuppressant", Abstract of NIH Grant R43AI34189 (1993).
International Search Report, Oct. 1995.
Berlin Vivian
Chiu Maria Isabel
Cottarel Guillaume
Damagnez Veronique
ARIAD Pharmaceuticals, Inc.
Clauss Isabelle M.
Slobodyansky Elizabeth
Vincent Matthew P.
LandOfFree
Immunosuppressant target proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunosuppressant target proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunosuppressant target proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-197078